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ABSTRACT 
 
Aim: To determine the prevalence of High and Low -level Mupirocin, resistance against MRSA from a tertiary care 
hospital in eastern UP was the aim of this study. Methods and Material: A total of 62 non duplicate previously 
confirmed MRSA isolates were included in this study. The Susceptibility testing andresult interpretation for 
determining the high and low level of mupirocin resistance was performed by disk diffusion method using 200 µg 
and 5 µg disc respectively as per Clinical and Laboratory Standards Institute (CLSI) M100-S25 recommendations.   
Results: A total of 60 isolates (96.8 %) were found sensitive to mupirocin, 2 isolates (3.2 %) had low-level 
mupirocin resistance whereas none of the isolates was found to have high-level mupirocin resistance. Conclusion: 
The high-level mupirocin-resistant is uncommon in our patient population. The Periodic monitoring is useful for 
detecting changing trends in mupirocin resistance as a risk of emergence of high level mupirocin resistant strains is 
there.   
Keywords: Mupirocin, MRSA, disk diffusion method. 
Introduction 
Methicillin-resistant Staphylococcus aureus (MRSA) is 
one of the most common pathogens responsible for 
hospital-acquired infections [1]. Common risk factor 
for the development of MRSA strain is indiscriminate 
use of antibiotics, intravenous drug use, prolonged stay 
in hospitals, and carriage of MRSA in anterior nares, 
axilla, and perineum [2]. Vancomycin and linezolid are 
commonly used drugs for systemic MRSA infection, 
while Mupirocin is successfully used as topical 
antibiotics for the treatment of skin infection and 
decolonization and eradication of MRSA from nasal 
carriers[3,4].  
The antimicrobial Mupirocin is chemically 
pseudomonic acid A, is derived from 
Pseudomonas fluorescens and is active against most 
‘Gram-positive’ and some ‘Gram-negative’ bacteria. 
Mupirocin competitively binds to bacterial isoleucyl-
tRNA synthetase, inhibits protein synthesis and 
ultimately leading to bacterial death[5].  
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Mupirocin is mainly bacteriostatic but appears 
bactericidal at lower pH in many parts of the skin. 
Increase use of mupirocin leads to outbreaks of 
resistance against MRSA to this antibiotic, 
however, the frequency of resistance is still low. Nasal 
application of mupirocin at clinically effective 
concentrations may result in the presence of low level 
of the antibiotic in the pharynx, which could induce the 
emergence of mupirocin-resistant MRSA [6]. 
Mupirocin-resistant strains are grouped into two 
distinct categories: low level (MupRL), with MICs of 
8–256 µg/ml, and high level (MupRH), with MICs 
≥512 µg/ml [7]. Susceptible strains are defined as those 
with a MIC ≤4 µg, showing zone diameters of ≥14 mm 
around 5 µg mupirocin discs [8,9]. Strains presenting 
diameters ≤14 mm are considered to be mupirocin 
resistant (either MupRH or MupRL).Clinical 
laboratories are able to differentiate Mup Susceptible 
strains using the 5 µg disc, but the resistant strains can 
only be distinguished empirically, as MupRH isolates 
show heavy growth around the 5 µg mupirocin disc, 
whereas MupRL isolates produced hazy zones of 
inhibition [10]. Low-level resistance is probably due to 
mutations in a chromosomally encoded IleS, is stable 
and non-transferable. Recent work has shown that the 
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substitution of a single amino acid in the synthetase of 
Escherichia coli significantly altered its mupirocin 
susceptibility [11,12].High-level resistance has been 
shown to be due in vivo to the acquisition of an 
additional novel IleS and also believed to be the result 
of a mutated gene on a plasmid [12,13]. However, 
others have postulated that there may be other 
mechanisms for resistance, e.g. an altered tRNA 
synthetase protein complex that might reduce the 
ability of mupirocin to gain access to IleS, enzymatic 
destruction has yet to be described [14]Mupirocin 
resistance is of significant concern for infection 
prevention and control personnel who are engaged in 
MRSA control efforts. Moreover, the presence of 
MRSA infection with mupirocin resistance 
significantly reduces the likelihood of MRSA 
eradication. Thus this study was planned to determine 
the prevalence of High and Low -level Mupirocin, 
resistance against MRSA from a tertiary care hospital 
in eastern UP.  
 
Material and methods 
 
The study was carried out in the Department of 
Microbiology, Institute of Medical Science Banaras 
Hindu University, Varanasi, U.P., India. The total 
duration of study is one year; period extends from July 
2015 to June 2016. A total of 62 non-duplicate MRSA 
isolates from various clinical specimens like pus, 
blood, urine, tracheal aspirates, sputum, central venous 
catheters tips, CSF and other sterile body fluids were 
randomly selected. MRSA isolates were identified by 
standard microbiological techniques. Methicillin 
resistance was screened by using cefoxitin disc (30 µg 
Himedia). After isolation and identification, the MRSA 
strains were kept at -200C in peptone/glycerol (30% 
w/v), and before Mupirocin susceptibility testing, the 
strains were purified twice on blood agar plates. 
Susceptibility to Mupirocin was determined by Kirby 
Bauer disc diffusion method on Muller Hinton Agar as 
per CLSI 2016.  High and low level of mupirocin 
resistance was determined by using 200 µg and 5 µg 
HiMEDIA disc respectively. Disc diffusion tests were 
carried out according to the guidelines of the Clinical 
and Laboratory Standards Institute (CLSI, 2016). 
Plates containing Mueller–Hinton agar (HiMEDIA) 
were swabbed in three directions with 0.5 McFarland 
inocula and 6 mm discs containing 5 µg and 
200 µg mupirocin were applied. The inoculated plates 
were incubated in ambient air at 37°C for 16 to 18 h. E. 
coli ATCC 25922 was used as control strains and zone 
of inhibition was interpreted by using CLSI M100-
S25(2016) breakpoints.  
 
Result 
 
   A total of 62 clinical MRSA isolates were included in 
this study. Table 1 shows the distribution of MRSA 
isolates obtained from various clinical samples. The 
highest number of methicillin-resistant staphylococcal 
strains were obtained from pus 24 (38.7 %) followed 
by blood 10 (16.1 %) and sputum 8 (12.9 %). 
 
Table 1: Distribution of MRSA isolates obtained from various clinical samples 
 
S. no Clinical specimens Number of isolates (n) Percentage (%) 
1 Pus 24 38.7 
2 Blood 10 16.1 
3 Sputum 8 12.9 
4 Tracheal aspirates 5 8.1 
5 Urine 3 4.8 
6 Central venous catheters tips 2 3.2 
7 CSF 1 1.6 
8 Other Sterile body fluids 9 14.5 
 Total 62 100 
  
Out of 62 isolates of MRSA tested, 60 isolates (96.8 %) were found sensitive to mupirocin, 2 isolates (3.2 %) had 
low-level mupirocin resistance whereas none of the isolates had high-level mupirocin resistance Table 2. 
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Table 2: Interpretative criteria proposed to determine the categories of mupirocin susceptibility by the disc 
diffusion method and results 
 
Inhibition zone diameter (mm) 
5 µg disc 
Inhibition zone diameter (mm)200 µg disc Interpretive criteria Results n (%) 
≥14 ≥14 MupS 60 (96.8) 
- ≥14 MupRL 02 (3.2) 
- - MupRH 0 
MupS – Mupirocin sensitive; MupRL – Mupirocin low-level resistance; MupRH - Mupirocin high-level resistance 
 
Discussion 
The first mupirocin resistant Clinical isolate was 
reported in 1987, and the resistance rate has been 
increasing ever since [15]. A Canadian study 
conducted by Simor et alreported an increase in 
mupirocin resistance among MRSA over time [16]. 
Perez- Fontan et al reported the emergence of 
mupirocin-resistant S. aureus in peritoneal dialysis 
patients who applied mupirocin for over 10 years [17]. 
In Korea, topical mupirocin has been used since 1994 
to eradicate staphylococcal infections in hospitals and 
the use of mupirocin has been dramatically increasing. 
However, there has been little awareness and research 
about mupirocin resistance. The study conducted in 
Korea up to 1999 failed to detect mupirocin-resistant 
strains [18]. Yun et al.first identified high-level 
resistant isolates in 2003 and the prevalence of 
mupirocin resistance was 5% [19] .Studies from 
various centres across the world report difference in the 
prevalence of mupirocin resistance. While a study  
from Loyola University Health Systems noted the 
 mupirocin resistance (MR) in 3.4% of MRSA carriers, 
and high-level MR in 0.62% of carriers, another study 
from south India found that rate of High-level 
mupirocin resistance to be 2% in MRSA 
strains[20,21].  
In our study, we looked for high-level and low-level 
mupirocin resistance among clinical isolates collected 
from a tertiary hospital in Varanasi, India. In our study 
we found 2 isolates (3.2%) showing low level 
mupirocin-resistant. As per Redhead et al., low-level 
mupirocin-resistant strains are not considered clinically 
significant, since the concentration of mupirocin in the 
2% ointment (20,000µg/ml) exceeds the MICs of low-
level mupirocin-resistant strains, so such strains can be 
treated by topical mupirocin [22]. On the contrary, 
high-level mupirocin resistance that cannot be treated 
with mupirocin are more clinically important.None of 
the isolates in this study were found to be high-level 
mupirocin resistant.Thus, our study indicates that high-
level mupirocin-resistant is uncommon in our patient 
population. However, there is always a chance of 
emergence of high level mupirocin resistant strains in 
our setting where mupirocin is frequently used for the 
decolonisation of MRSA strains among health care 
workers.In this scenario periodic monitoring would be 
useful for detecting changing trends in mupirocin 
resistance. 
The increasing number of reports of high-level 
mupirocin resistance could mean the potential loss of 
one of the major treatment methods for controlling 
MRSA. Therefore, mupirocin treatment should be used 
cautiously and judiciously 
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